8-K: Clorox Q2 Fiscal Year 2025 Results: Sales Decline, EPS Surges, Outlook Updated

Clorox reported a decrease in net sales but an increase in diluted EPS for Q2 fiscal year 2025, and updated its full-year outlook, including the wind down of the Glad bags and wraps joint venture with P&G.

Summary

• Clorox reported its Q2 fiscal year 2025 results, which ended December 31, 2024.
• Net sales decreased by 15% to $1.69 billion, primarily due to lapping the impact of retail inventory restoration following the August 2023 cyberattack and divestitures.
• Organic sales decreased by 9%.
• Gross margin increased by 30 basis points to 43.8%.
• Diluted net earnings per share (EPS) increased by 105% to $1.54.
• Adjusted EPS decreased by 28% to $1.55.
• Year-to-date net cash provided by operations was $401 million, a 132% increase.
• Clorox and P&G will wind down their Glad bags and wraps joint venture as of January 31, 2026, with Clorox intending to acquire P&G's 20% interest.
• The company updated its fiscal year 2025 outlook, expecting net sales to be down 1% to up 2% and organic sales to be up 4% to 7%.
• Gross margin is now expected to be up 125 to 150 basis points.
• Fiscal year diluted EPS is now expected to be between $5.52 and $5.92, and adjusted EPS is expected to be between $6.95 and $7.35.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While sales declined, EPS increased significantly, and the company is taking strategic actions like acquiring full control of the Glad business. The updated outlook is cautiously optimistic.

Positives

• Diluted net earnings per share (diluted EPS) increased by 105% to $1.54.
• Year-to-date net cash provided by operations was $401 million compared to $173 million in the year-ago period, representing a 132% increase.
• Gross margin is now expected to be up 125 to 150 basis points.
• Clorox achieved the ninth consecutive quarter of gross margin expansion, supported by another strong quarter of cost savings.
• Clorox grew share in seven of its eight categories, supported by strong demand creation plans as the company laps the impact of the cyberattack.

Negatives

• Net sales decreased by 15% to $1.69 billion.
• Organic sales decreased by 9%.
• Adjusted EPS decreased by 28% to $1.55.
• Health and Wellness net sales decreased 13%, driven by 11 points of lower volume and 2 points of unfavorable price mix.
• Household net sales decreased 11%, driven by 11 points of lower volume.
• Lifestyle net sales decreased 16%, driven by 16 points of lower volume.
• International net sales decreased 12%, mainly driven by the impact of the Argentina divestiture.

Risks

• The company's performance is subject to unfavorable general economic and geopolitical conditions.
• The company faces intense competition in its markets.
• Volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services could negatively impact the company.
• The company's recovery from the August 2023 cyberattack poses ongoing risks.
• The company's ability to implement and generate cost savings and efficiencies is subject to risk.

Future Outlook

The company expects net sales to be down 1% to up 2% and organic sales to be up 4% to 7% for fiscal year 2025. Gross margin is expected to be up 125 to 150 basis points. Fiscal year diluted EPS is expected to be between $5.52 and $5.92, and adjusted EPS is expected to be between $6.95 and $7.35.

Management Comments

• We achieved better-than-expected results across sales, margin and EPS in the second quarter due to our strong demand creation plans, which also supported our share growth, said Chair and CEO Linda Rendle.
• We are further advancing our transformation as we embark upon a significant milestone with our Enterprise Resource Planning transition in the U.S., resulting in our updated outlook, said Chair and CEO Linda Rendle.
• We are excited to assume full control of the Glad business and thank P&G for their productive partnership over the past two decades, said Rendle.

Industry Context

The announcement reflects Clorox's efforts to navigate a challenging macroeconomic environment, including supply chain disruptions and inflation, while also focusing on strategic initiatives such as portfolio optimization and digital transformation. The wind down of the Glad joint venture and Clorox's acquisition of P&G's interest signal a strategic move to consolidate control over a key brand.

Comparison to Industry Standards

• Comparing Clorox's performance to peers like Procter & Gamble (P&G) and Unilever, it's important to consider the specific challenges each company faces.
• P&G, for example, has a broader portfolio and may experience different growth dynamics.
• Unilever, with its significant international presence, is more exposed to currency fluctuations and emerging market volatility.
• Clorox's gross margin of 43.8% can be benchmarked against the average gross margins of its competitors in the household and personal care products industry.
• Companies like Church & Dwight often serve as useful comparisons due to their focus on similar product categories.

Stakeholder Impact

• Shareholders may react to the mixed results, with the sales decline potentially offset by the EPS increase and positive outlook.
• Employees may be affected by the ongoing transformation initiatives and the wind down of the Glad joint venture.
• Customers may see changes in product offerings and innovation as Clorox focuses on its core brands.
• Suppliers may be impacted by changes in Clorox's supply chain and sourcing strategies.

Next Steps

• Clorox will post prepared management remarks regarding its second quarter fiscal year 2025 results.
• The company will host a live Q&A audio webcast with Chair and CEO Linda Rendle, Chief Financial Officer Kevin Jacobsen and Treasurer and incoming Chief Financial Officer Luc Bellet to discuss the results.

Key Dates